Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy

Optimizing the anticoagulation therapy is of pivotal importance in patients with a malignant tumor, as venous thromboembolism (VTE) has become the second-leading cause of death in this population. Cancer can highly increase the risk of thrombosis and bleeding. Consequently, the management of cancer-...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Vincenzo, Falco, Luigi, Tessitore, Viviana, Mauriello, Alfredo, Catapano, Dario, Napolitano, Nicola, Tariq, Moiz, Caturano, Alfredo, Ciccarelli, Giovanni, D’Andrea, Antonello, Giordano, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532829/
https://www.ncbi.nlm.nih.gov/pubmed/37763292
http://dx.doi.org/10.3390/life13091888
Descripción
Sumario:Optimizing the anticoagulation therapy is of pivotal importance in patients with a malignant tumor, as venous thromboembolism (VTE) has become the second-leading cause of death in this population. Cancer can highly increase the risk of thrombosis and bleeding. Consequently, the management of cancer-associated VTE is complex. In recent years, translational research has intensified, and several studies have highlighted the role of inflammatory cytokines in cancer growth and progression. Simultaneously, the pleiotropic effects of anticoagulants currently recommended for VTE have emerged. In this review, we describe the anti-inflammatory and anticancer effects of both direct oral anticoagulants (DOACs) and low-molecular-weight heparins (LWMHs).

Ejemplares similares